scientific posters & presentations
You are here
Scientific Presentations
CK2 PROGRAM
Discovery of CX-4945, the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer
DOWNLOAD PDF
CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis in Multiple Myeloma Cells
DOWNLOAD PDF
A potent and selective inhibitor of CK2, modulates PI3K/AKT signaling and phosphorylation of p21 in vitro and in vivo
DOWNLOAD PDF
Scientific Posters
CK2 PROGRAM
Discovery and Biological Characterization of CX-8184, A Potent Inhibitor of Protein Kinase CK2
DOWNLOAD PDF
Findings from the Phase I Clinical Trials of CX-4945, an Orally Bioavailable Inhibitor of CK2
DOWNLOAD PDF
CX-4945, an Inhibitor of Protein Kinase CK2, Potentiates the Antitumor Activity of Platinum Chemotherapy in Models of Ovarian Cancer by Preventing Phosphorylation of XRCC1 and MDC1 and Disrupting DNA Damage Repair
DOWNLOAD PDF
The CK2 Inhibitor CX-4945 Enhances the Antitumor Activity of EGFR-targeted Agents by Attenuating Signaling in the PI3K-Akt-mTOR Pathway
DOWNLOAD PDF
Clinical Pharmacokinetics and Pharmacodynamics of CX-4945, a Novel Inhibitor of Protein Kinase CK2: Interim Report from the Phase 1 Clinical Trial
DOWNLOAD PDF
CX-4945, an Inhibitor of Protein Kinase CK2, Disrupts DNA Damage Repair, Potentiates Apoptosis and Enhances Antitumor Activity of Gemcitabine in a Model of Ovarian Cancer
DOWNLOAD PDF
Combined Inhibition of EGFR and Protein Kinase CK2 Synergistically Blocks Phosphorylation of Ribosomal Protein S6, Induces Apoptosis in Cancer Cells and Displays Enhanced Antitumor Activity in Xenograft Models
DOWNLOAD PDF
Quantitative Determination of CX-4945, a Novel CK2 Kinase Inhibitor, in Rat, Dog and Human Plasma Using LC/MS/MS
DOWNLOAD PDF
CX-4945, a Novel Small Molecule Inhibitor of CK2 Protein Kinase, Reduces Hyperactivated AKT Signaling and Synergizes with AKT Inhibitors in Breast Cancer Cells
DOWNLOAD PDF
Discovery and characterization of CX-4945, a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase 1 initiated
DOWNLOAD PDF
CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the vascular endothelium and suppressing hypoxia-activated Hif-1α transcription
DOWNLOAD PDF
POL I PROGRAM
CX-5461, a Non-Genotoxic Activator of p53 through Selective Inhibition of RNA Polymerase I for the Treatment of Hematological Cancers
DOWNLOAD PDF
RNA Polymerase I: A novel target in the treatment of MYC-driven malignancy
DOWNLOAD PDF
CX-5461 a Novel, Orally Bioavailable and Selective Small Molecule Inhibitor of RNA Polymerase I Transcription Induces Autophagy and Shows Potent Anti-tumor Activity
DOWNLOAD PDF
CX-5461 Selectively Inhibits SL1 Function of RNA Polymerase I Transcription in the Ribosome Biogenesis Pathway and Exhibits Potent Antitumor Activity in Cancer Models
DOWNLOAD PDF
PIM PROGRAM
Discovery of selective small molecule Pan-PIM kinase inhibitors with potent oral efficacy in murine xenograft models
DOWNLOAD PDF
